Mitochondria in cardiac hypertrophy and heart failure

MG Rosca, B Tandler, CL Hoppel - Journal of molecular and cellular …, 2013 - Elsevier
MG Rosca, B Tandler, CL Hoppel
Journal of molecular and cellular cardiology, 2013Elsevier
Heart failure (HF) frequently is the unfavorable outcome of pathological heart hypertrophy. In
contrast to physiological cardiac hypertrophy, which occurs in response to exercise and
leads to full adaptation of contractility to the increased wall stress, pathological hypertrophy
occurs in response to volume or pressure overload, ultimately leading to contractile
dysfunction and HF. Because cardiac hypertrophy impairs the relationship between ATP
demand and production, mitochondrial bioenergetics must keep up with the cardiac …
Heart failure (HF) frequently is the unfavorable outcome of pathological heart hypertrophy. In contrast to physiological cardiac hypertrophy, which occurs in response to exercise and leads to full adaptation of contractility to the increased wall stress, pathological hypertrophy occurs in response to volume or pressure overload, ultimately leading to contractile dysfunction and HF. Because cardiac hypertrophy impairs the relationship between ATP demand and production, mitochondrial bioenergetics must keep up with the cardiac hypertrophic phenotype. We review data regarding the mitochondrial proteomic and energetic remodeling in cardiac hypertrophy, as well as the temporal and causal relationships between mitochondrial failure to match the increased energy demand and progression to cardiac decompensation. We suggest that the maladaptive effect of sustained neuroendocrine signals on mitochondria leads to bioenergetic fading which contributes to the progression from cardiac hypertrophy to failure. This article is part of a Special Issue entitled "Focus on Cardiac Metabolism".
Elsevier